
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen Inc is poised for significant financial growth, with management projecting product sales exceeding $18 million in Q1 2026, which indicates a remarkable sequential growth of over five-fold. This anticipated sales increase is supported by commercial momentum, the activation of treatment centers, and a forthcoming reimbursement tailwind from a permanent J-code effective April 1, 2026, leading to enhanced adoption by community physicians. The company's promising clinical pipeline and innovative technology platforms further underpin the positive outlook for its financial performance in the biopharmaceutical market.
Bears say
Precigen Inc. reported disappointing financial results for the fourth quarter of 2025, with sales of $3.4 million significantly below the consensus estimate of $8.3 million. The company also posted a net loss of $0.04 per diluted share, which, while better than the estimated loss of $0.08 per share, still reflects a challenging financial position. These figures indicate ongoing difficulties in revenue generation and profitability, contributing to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares